Answers are grounded in this paper and cite their sources.
Introduction: The exponential increase in obesity is responsible for the increased prevalence of obstructive sleep apnoea (OSA). Weight loss is critical to improvement in OSA. Glucagon-like peptide-1 receptor (GLP1R) agonism-based therapies (GLP1RA-BT) have been associated with significant weight loss. Several randomized controlled trials have been published evaluating the use of GLP1RA-BT on OSA. However, the literature review revealed that no systematic review and meta-analysis (SRM) has been published evaluating the efficacy and safety of GLP1RA-BT in OSA. Methods: Electronic databases were searched for studies documenting the use of GLP1RA-BT in OSA. The primary outcome was to evaluate the impact on the apnea–hypopnea index (AHI). Secondary outcomes were to evaluate the impact on percent change in AHI, Epworth Sleepiness Score, body weight, blood pressure, and side-effect profile. Results: From initially screened 59 articles, data from 4 articles having 5 different randomized cohorts (937 patients) were analysed in this SRM. Use of GLP1RA-BT was associated with a significant reduction in AHI [MD-12.50 events/ hour (95% CI:−17.33 – -7.67); P < 0.001; I 2 =95%], percent-reduction in AHI [MD-52.17% (95% CI: -64.49 – -39.85); P < 0.001; I 2 = 0%], percent-reduction in body-weight [MD-12.46% (95% CI:-22.54 – -2.39); P < 0.001; I 2 = 99%] and systolic blood-pressure [MD -4.59 mm of Hg (95% CI:-6.61 – -2.58); P < 0.001; I 2 = 67%]. The considerable heterogeneity was because of greater improvement in outcomes withtirzepatide compared to liraglutide. The occurrence of nausea [RR4.23 (95% CI: 2.73–6.55); P < 0.001; I 2 = 0%], vomiting [RR4.22 (95% CI: 2.12–8.41); P < 0.001; I 2 = 0%], diarrhoea [RR2.81 (95% CI: 1.84–4.31); P < 0.001; I 2 = 0%], and constipation [RR4.51 (95% CI: 2.47–8.26); P < 0.001; I 2 = 0%] were significantly higher with GLP1RA-BT compared to placebo. Conclusion: This SRM provides encouraging data on the use of GLP1RA-BT in improving different respiratory aspects of OSA and reducing body weight and blood pressure.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: